Hurdles for Phage Therapy (PT) to Become a Reality

Alternative treatment modes for antibiotic-resistant bacterial pathogens have become a public health priority. Bacteriophages are bacterial viruses that infect and lyse bacterial cells. Since bacteriophages are frequently bacterial host species-specific and can often also infect antibiotic-resistant...

Full description

Saved in:
Bibliographic Details
:
Year of Publication:2019
Language:English
Physical Description:1 electronic resource (484 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993548811304498
ctrlnum (CKB)4100000010106080
(oapen)https://directory.doabooks.org/handle/20.500.12854/49693
(EXLCZ)994100000010106080
collection bib_alma
record_format marc
spelling Brüssow, Harald auth
Hurdles for Phage Therapy (PT) to Become a Reality
Hurdles for Phage Therapy
MDPI - Multidisciplinary Digital Publishing Institute 2019
1 electronic resource (484 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Alternative treatment modes for antibiotic-resistant bacterial pathogens have become a public health priority. Bacteriophages are bacterial viruses that infect and lyse bacterial cells. Since bacteriophages are frequently bacterial host species-specific and can often also infect antibiotic-resistant bacterial cells, they could represent ideal antimicrobials for fighting the antibiotic resistance crisis. The medical use of bacteriophages has become known as phage therapy. It is widely used in Russia, where phage cocktails are sold in pharmacies as an over-the-counter drug. However, no phage product has been registered for medical purposes outside of the former Soviet Union. The current Special Issue of Viruses contains a collection of papers from opinion leaders in the field who explore hurdles to the introduction of phage therapy in western countries. The articles cover diverse topics ranging from patent to regulatory issues, the targeting of suitable bacterial infections, and the selection and characterization of safe and efficient phage cocktails. Phage resistance is discussed, and gaps in our knowledge of phage–bacterium interactions in the mammalian body are revealed, while other articles explore the use of phages in food production and processing.
English
alginate
abortive infection
bacterial resistance
bacteriophages
ATMP
MALDI-MS
adaptation
Bacteriophage
horizontal gene transfer
adaptive immunity
co-evolution
Listeria ivanovii
personalised medicines
pH stability
phage-human host interaction
vB_SauM-fRuSau02
antimicrobial resistance
phagodisinfection
biofilm
capsule depolymerase
animal model
phage cocktails
Enterococcus
cases report
zoonosis
resistance
magistral formula
experimental therapy
Belgium
phage therapy
E. faecalis
nontraditional antibacterial
industrial phage application
Democratic Republic of the Congo
OrthoMCL
Germany
high-throughput sequencing
antimicrobial
infection
antibiotic therapy
Kayvirus
phages
Twortlikevirus
bacterial disease
human host
Pseudomonas aeruginosa
phage
multidrug-resistant bacteria
bacterial infection
Salmonella Typhi
rhamnopolysaccharide
compassionate use
crop production
compounding pharmacy
antimicrobial resistance (AMR)
best practices
bacteriophage efficacy
phage sensitivity
antibiotic-resistance
antibiotic
lysins
PTMP
Escherichia coli
typhoid fever
patent landscape
phage preparation
innate immunity
anti-phage antibodies
immunology
Staphylococcus aureus
global health
clinical trial
adsorption
Brussels
phage-resistance
Galleria mellonella
science communication
history of science
virus-host interactions
foodborne illness
prophage
resistance management
biofilms
IND
immunomodulation
frequency of resistance
capsule
gastrointestinal tract
phage-host interactions
disinfection
production
bacteriophage therapy
bacteriophage
Staphylococcus
magistral preparation
extended-spectrum beta lactamases (ESBL)
Viral proteins
antibiotic resistance
genomics
phage biocontrol
therapy
target selection
viral genomes
evolution
pharmaceutical paradigm shift
personalized medicine
pharmaceutical legislation
food safety
regulation
virulence
developing countries
infectious disease
regulatory framework
sustainable agriculture
Klebsiella pneumoniae
3-03921-391-1
language English
format eBook
author Brüssow, Harald
spellingShingle Brüssow, Harald
Hurdles for Phage Therapy (PT) to Become a Reality
author_facet Brüssow, Harald
author_variant h b hb
author_sort Brüssow, Harald
title Hurdles for Phage Therapy (PT) to Become a Reality
title_full Hurdles for Phage Therapy (PT) to Become a Reality
title_fullStr Hurdles for Phage Therapy (PT) to Become a Reality
title_full_unstemmed Hurdles for Phage Therapy (PT) to Become a Reality
title_auth Hurdles for Phage Therapy (PT) to Become a Reality
title_alt Hurdles for Phage Therapy
title_new Hurdles for Phage Therapy (PT) to Become a Reality
title_sort hurdles for phage therapy (pt) to become a reality
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2019
physical 1 electronic resource (484 p.)
isbn 3-03921-392-X
3-03921-391-1
illustrated Not Illustrated
work_keys_str_mv AT brussowharald hurdlesforphagetherapypttobecomeareality
AT brussowharald hurdlesforphagetherapy
status_str n
ids_txt_mv (CKB)4100000010106080
(oapen)https://directory.doabooks.org/handle/20.500.12854/49693
(EXLCZ)994100000010106080
carrierType_str_mv cr
is_hierarchy_title Hurdles for Phage Therapy (PT) to Become a Reality
_version_ 1796649014342451201
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05914nam-a2201657z--4500</leader><controlfield tag="001">993548811304498</controlfield><controlfield tag="005">20231214132829.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2019 xx |||||o ||| 0|eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-03921-392-X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4100000010106080</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/49693</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994100000010106080</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Brüssow, Harald</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hurdles for Phage Therapy (PT) to Become a Reality</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Hurdles for Phage Therapy </subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (484 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Alternative treatment modes for antibiotic-resistant bacterial pathogens have become a public health priority. Bacteriophages are bacterial viruses that infect and lyse bacterial cells. Since bacteriophages are frequently bacterial host species-specific and can often also infect antibiotic-resistant bacterial cells, they could represent ideal antimicrobials for fighting the antibiotic resistance crisis. The medical use of bacteriophages has become known as phage therapy. It is widely used in Russia, where phage cocktails are sold in pharmacies as an over-the-counter drug. However, no phage product has been registered for medical purposes outside of the former Soviet Union. The current Special Issue of Viruses contains a collection of papers from opinion leaders in the field who explore hurdles to the introduction of phage therapy in western countries. The articles cover diverse topics ranging from patent to regulatory issues, the targeting of suitable bacterial infections, and the selection and characterization of safe and efficient phage cocktails. Phage resistance is discussed, and gaps in our knowledge of phage–bacterium interactions in the mammalian body are revealed, while other articles explore the use of phages in food production and processing.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">alginate</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">abortive infection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacterial resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacteriophages</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ATMP</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MALDI-MS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adaptation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Bacteriophage</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">horizontal gene transfer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adaptive immunity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">co-evolution</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Listeria ivanovii</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">personalised medicines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pH stability</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage-human host interaction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vB_SauM-fRuSau02</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antimicrobial resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phagodisinfection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biofilm</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">capsule depolymerase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">animal model</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage cocktails</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Enterococcus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cases report</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">zoonosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">magistral formula</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">experimental therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Belgium</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">E. faecalis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nontraditional antibacterial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">industrial phage application</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Democratic Republic of the Congo</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">OrthoMCL</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Germany</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">high-throughput sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antimicrobial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">infection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibiotic therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Kayvirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phages</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Twortlikevirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacterial disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">human host</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Pseudomonas aeruginosa</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multidrug-resistant bacteria</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacterial infection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Salmonella Typhi</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">rhamnopolysaccharide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">compassionate use</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">crop production</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">compounding pharmacy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antimicrobial resistance (AMR)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">best practices</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacteriophage efficacy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage sensitivity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibiotic-resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibiotic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lysins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PTMP</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Escherichia coli</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">typhoid fever</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">patent landscape</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage preparation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">innate immunity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-phage antibodies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Staphylococcus aureus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">global health</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical trial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adsorption</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Brussels</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage-resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Galleria mellonella</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">science communication</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">history of science</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">virus-host interactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">foodborne illness</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prophage</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">resistance management</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biofilms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">IND</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunomodulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">frequency of resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">capsule</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gastrointestinal tract</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage-host interactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">disinfection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">production</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacteriophage therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bacteriophage</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Staphylococcus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">magistral preparation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">extended-spectrum beta lactamases (ESBL)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Viral proteins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibiotic resistance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage biocontrol</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">target selection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">viral genomes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">evolution</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmaceutical paradigm shift</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">personalized medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmaceutical legislation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">food safety</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">regulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">virulence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">developing countries</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">infectious disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">regulatory framework</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sustainable agriculture</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Klebsiella pneumoniae</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-03921-391-1</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:32:38 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2020-02-01 22:26:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5338895950004498&amp;Force_direct=true</subfield><subfield code="Z">5338895950004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338895950004498</subfield></datafield></record></collection>